<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04615364</url>
  </required_header>
  <id_info>
    <org_study_id>2019-022</org_study_id>
    <nct_id>NCT04615364</nct_id>
  </id_info>
  <brief_title>Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia</brief_title>
  <acronym>DENWOLUTION</acronym>
  <official_title>Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Pasteur de Nouvelle-Calédonie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Territorial de Nouvelle-Calédonie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Pasteur</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major&#xD;
      public health problem, especially in tropical and sub-tropical countries. A promising&#xD;
      strategy aimed at blocking the circulation of arboviruses is to release Aedes aegypti&#xD;
      mosquitoes carrying the endosymbiotic bacterium Wolbachia. In 2019, the Wolbachia strategy&#xD;
      was implemented in Nouméa as part of the World Mosquito Program. This intervention will&#xD;
      modify the epidemiological profile of arboviruses in New Caledonia.&#xD;
&#xD;
      Epidemiological surveillance of arboviruses requires molecular characterization of the virus&#xD;
      contained in the serum obtained from the blood collected from patients. This molecular&#xD;
      characterization by RNA isolation techniques, RT-qPCR monitoring and sequencing allows the&#xD;
      construction of phylogenetic trees.&#xD;
&#xD;
      In the context of the implementation of the World Mosquito Program in Nouméa, the&#xD;
      investigators plan to follow the molecular evolution of arboviruses, over the period&#xD;
      preceding the releases of mosquitoes carrying Wolbachia (from 1995 to 2019) then over a&#xD;
      period of 5 years. following the releases.&#xD;
&#xD;
      At the same time, the virus can be isolated by cell culture techniques and in vitro&#xD;
      infections, allowing its study in vitro in cells or in vivo in mosquitoes. This study allows&#xD;
      us to measure the impact of the Wolbachia strategy on the evolution of the virus's ability to&#xD;
      replicate in cells in the presence of Wolbachia and to be transmitted by the mosquito.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Collection of blood samples from patients with arbovirus infection&#xD;
&#xD;
      This study is a non-interventional study with retrospective part.&#xD;
&#xD;
      This study will improve :&#xD;
&#xD;
        -  the assessment of the molecular evolution of arboviruses in the period preceding the&#xD;
           implementation of the Wolbachia strategy&#xD;
&#xD;
        -  the knowledge of the impact of Wolbachia on the diversity and molecular evolution of&#xD;
           arboviruses&#xD;
&#xD;
        -  the understanding of arbovirus transmission and replication mechanisms in the presence&#xD;
           of Wolbachia&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2020</start_date>
  <completion_date type="Anticipated">July 17, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 17, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>arbovirus genome sequencing</measure>
    <time_frame>5 years</time_frame>
    <description>Whole genome sequencing of virus extracted of blood samples from patients collected from 1995 to 2024</description>
  </primary_outcome>
  <primary_outcome>
    <measure>genetic evolution of arbovirus strains</measure>
    <time_frame>5 years</time_frame>
    <description>bioinformatical analysis of the genome of the strains of arbovirus contained in serum samples collected from 1995 to 2024</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>measurement of the impact of Wolbachia on the virus genetic evolution</measure>
    <time_frame>5 years</time_frame>
    <description>comparison of viral genomes extracted from blood samples collected from 1995 to 2024</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of the ability of these viruses to replicate in the presence of Wolbachia</measure>
    <time_frame>5 years</time_frame>
    <description>infection of cell lines with virus strains isolated and amplified from patient blood samples collected from 1995 to 2024</description>
  </secondary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Arbovirus Infections</condition>
  <condition>Dengue</condition>
  <condition>Zika</condition>
  <condition>Chikungunya</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient infected by arboviruses&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Appearance of clinical signs suggestive of an infection with an arbovirus in the 7&#xD;
             days preceding the blood sample,&#xD;
&#xD;
          -  Diagnostic confirmation by RT-qPCR of mono-infection with dengue virus or another&#xD;
             arbovirus.&#xD;
&#xD;
          -  Patients or their representative (s) informed of the possible secondary use for&#xD;
             research purposes of the samples initially taken for diagnostic purposes and their&#xD;
             derivatives, and who have not since expressed their opposition to the secondary use of&#xD;
             the samples diagnostics or their derivatives for research,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented opposition from a patient or his representative (s)&#xD;
&#xD;
          -  Previously established viral load too low.&#xD;
&#xD;
          -  Sample obtained from a sample taken more than 7 days after the appearance of clinical&#xD;
             signs of infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myrielle Dupont-Rouzeyrol, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Pasteur de Nouvelle-Calédonie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Myrielle Dupont-Rouzeyrol, PhD</last_name>
    <phone>+687 27 75 30</phone>
    <email>mdupont@pasteur.nc</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Inizan, PhD</last_name>
    <phone>+687 27 26 66</phone>
    <email>cinizan@pasteur.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Territorial</name>
      <address>
        <city>Dumbéa Sur Mer</city>
        <state>Nouvelle-Calédonie</state>
        <zip>98 835</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann-Claire Gourinat, MD</last_name>
      <phone>+687 208000</phone>
      <email>ann-claire.gourinat@cht.nc</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>New Caledonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arbovirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

